These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 35258698

  • 1. Association of androgen excess and bone mineral density in women with classical congenital adrenal hyperplasia with 21-hydroxylase deficiency.
    Lee DH, Kong SH, Jang HN, Ahn CH, Lim SG, Lee YA, Kim SW, Kim JH.
    Arch Osteoporos; 2022 Mar 08; 17(1):45. PubMed ID: 35258698
    [Abstract] [Full Text] [Related]

  • 2. Bone mineral density and fractures in congenital adrenal hyperplasia: Findings from the dsd-LIFE study.
    Riehl G, Reisch N, Roehle R, Claahsen van der Grinten H, Falhammar H, Quinkler M.
    Clin Endocrinol (Oxf); 2020 Apr 08; 92(4):284-294. PubMed ID: 31886890
    [Abstract] [Full Text] [Related]

  • 3. Effects of androgen excess and glucocorticoid exposure on bone health in adult patients with 21-hydroxylase deficiency.
    Auer MK, Paizoni L, Hofbauer LC, Rauner M, Chen Y, Schmidt H, Huebner A, Bidlingmaier M, Reisch N.
    J Steroid Biochem Mol Biol; 2020 Nov 08; 204():105734. PubMed ID: 32784048
    [Abstract] [Full Text] [Related]

  • 4. Bone Mass in Young Patients with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.
    Espinosa Reyes TM, Leyva González G, Domínguez Alonso E, Falhammar H.
    Horm Res Paediatr; 2021 Nov 08; 94(1-2):1-8. PubMed ID: 34044395
    [Abstract] [Full Text] [Related]

  • 5. Cortical bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    El-Maouche D, Collier S, Prasad M, Reynolds JC, Merke DP.
    Clin Endocrinol (Oxf); 2015 Mar 08; 82(3):330-7. PubMed ID: 24862755
    [Abstract] [Full Text] [Related]

  • 6. Effect of long-term glucocorticoid therapy on bone mineral density of the patients with congenital adrenal hyperplasia.
    Ünal S, Alikaşifoğlu A, Özön A, Gönç N, Kandemir N.
    Turk J Pediatr; 2020 Mar 08; 62(3):359-366. PubMed ID: 32558409
    [Abstract] [Full Text] [Related]

  • 7. Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Ceccato F, Barbot M, Albiger N, Zilio M, De Toni P, Luisetto G, Zaninotto M, Greggio NA, Boscaro M, Scaroni C, Camozzi V.
    Eur J Endocrinol; 2016 Aug 08; 175(2):101-6. PubMed ID: 27185866
    [Abstract] [Full Text] [Related]

  • 8. Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia.
    Guo CY, Weetman AP, Eastell R.
    Clin Endocrinol (Oxf); 1996 Nov 08; 45(5):535-41. PubMed ID: 8977749
    [Abstract] [Full Text] [Related]

  • 9. Bone mineral density and body composition in prepubertal and adolescent patients with the classical form of 21-hydroxylase deficiency.
    Sahakitrungruang T, Wacharasindhu S, Supornsilchai V, Srivuthana S, Kingpetch K.
    J Med Assoc Thai; 2008 May 08; 91(5):705-10. PubMed ID: 18672636
    [Abstract] [Full Text] [Related]

  • 10. Bone mineral density in girls with classical congenital adrenal hyperplasia due to CYP21 deficiency.
    Elnecave RH, Kopacek C, Rigatto M, Keller Brenner J, Sisson de Castro JA.
    J Pediatr Endocrinol Metab; 2008 Dec 08; 21(12):1155-62. PubMed ID: 19189689
    [Abstract] [Full Text] [Related]

  • 11. Normal bone health in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy.
    Borges JH, de Oliveira DM, de Lemos-Marini SHV, Geloneze B, Guerra-Júnior G, Gonçalves EM.
    Osteoporos Int; 2022 Jan 08; 33(1):283-291. PubMed ID: 34406442
    [Abstract] [Full Text] [Related]

  • 12. Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia.
    King JA, Wisniewski AB, Bankowski BJ, Carson KA, Zacur HA, Migeon CJ.
    J Clin Endocrinol Metab; 2006 Mar 08; 91(3):865-9. PubMed ID: 16278269
    [Abstract] [Full Text] [Related]

  • 13. Bone mineral density and body composition in children with congenital adrenal hyperplasia.
    Halper A, Sanchez B, Hodges JS, Kelly AS, Dengel D, Nathan BM, Petryk A, Sarafoglou K.
    Clin Endocrinol (Oxf); 2018 Jun 08; 88(6):813-819. PubMed ID: 29460378
    [Abstract] [Full Text] [Related]

  • 14. Correlation of Bone Mineral Parameters with Anthropometric Measurements and the Effect of Glucocorticoids on Bone Mineral Parameters in Congenital Adrenal Hyperplasia.
    Ganesh R, Suresh N, Janakiraman L, Ravikumar K.
    Indian J Pediatr; 2016 Feb 08; 83(2):126-30. PubMed ID: 26223873
    [Abstract] [Full Text] [Related]

  • 15. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency.
    Chakhtoura Z, Bachelot A, Samara-Boustani D, Ruiz JC, Donadille B, Dulon J, Christin-Maître S, Bouvattier C, Raux-Demay MC, Bouchard P, Carel JC, Leger J, Kuttenn F, Polak M, Touraine P, Centre des Maladies Endocriniennes Rares de la Croissance and Association Surrénales.
    Eur J Endocrinol; 2008 Jun 08; 158(6):879-87. PubMed ID: 18390993
    [Abstract] [Full Text] [Related]

  • 16. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy.
    Koetz KR, Ventz M, Diederich S, Quinkler M.
    J Clin Endocrinol Metab; 2012 Jan 08; 97(1):85-92. PubMed ID: 21994966
    [Abstract] [Full Text] [Related]

  • 17. Real-world impact of glucocorticoid replacement therapy on bone mineral density: retrospective experience of a large single-center CAH cohort spanning 24 years.
    Iervolino LL, Ferraz-de-Souza B, Martin RM, Costa FC, Miranda MC, Mendonça BB, Bachega TS.
    Osteoporos Int; 2020 May 08; 31(5):905-912. PubMed ID: 31897546
    [Abstract] [Full Text] [Related]

  • 18. Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Bachelot A, Plu-Bureau G, Thibaud E, Laborde K, Pinto G, Samara D, Nihoul-Fékété C, Kuttenn F, Polak M, Touraine P.
    Horm Res; 2007 May 08; 67(6):268-76. PubMed ID: 17170529
    [Abstract] [Full Text] [Related]

  • 19. Gonadotropin-Releasing Hormone Agonist Therapy and Longitudinal Bone Mineral Density in Congenital Adrenal Hyperplasia.
    Flokas ME, Wakim P, Kollender S, Sinaii N, Merke DP.
    J Clin Endocrinol Metab; 2024 Jan 18; 109(2):498-504. PubMed ID: 37643900
    [Abstract] [Full Text] [Related]

  • 20. The effect of glucocorticoid replacement therapy on bone mineral density in children with congenital adrenal hyperplasia.
    Cetinkaya S, Kara C.
    J Pediatr Endocrinol Metab; 2011 Jan 18; 24(5-6):265-9. PubMed ID: 21823521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.